<DOC>
	<DOCNO>NCT00641043</DOCNO>
	<brief_summary>The objective current study investigate efficacy , safety tolerability BI 1356 ( Linagliptin ) ( 5 mg / daily ) compare placebo give 24 week initial combination therapy pioglitazone 30 mg patient type 2 diabetes mellitus insufficient glycaemic control .</brief_summary>
	<brief_title>Efficacy v Placebo Initial Combination Therapy With Pioglitazone</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed date write Informed Consent ( IC ) date Visit 1a accordance Good Clinical Practice ( GCP ) local legislation 2 . Patients diagnosis type 2 diabetes mellitus treatment naive previously treat oral hypoglycaemic agent ; antidiabetic therapy unchanged ten week prior inform consent . 3 . Glycosylated haemoglobin A1 ( HbA1c ) 7.511 % Visit 2 ( Start Runin ) . 4 . Male female patient age &gt; = 18 &lt; = 80 year Visit 1a ( Screening ) . 5 . Body Mass Index ( BMI ) &lt; = 40 kg/m2 Visit 1a ( Screening ) 6 . Signed date write informed consent prior admission study accordance GCP local legislation . Exclusion criterion : 1 . Myocardial infarction , stroke Transient Isquemic Atack ( TIA ) within 6 month prior Inform Consent ( IC ) 2 . Impaired hepatic function , define serum level either Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) , alkaline phosphatase 3 x upper limit normal ( ULN ) determine Visit 1a . 3 . Known hypersensitivity allergy investigational product excipients and/or hydrochloride pioglitazone excipients 4 . Treatment Glucagonlike peptide1 ( GLP1 ) analogue / agonist within 3 month prior IC . 5 . Treatment insulin within 3 month prior IC 6 . Treatment antiobesity drug 3 month prior IC . 7 . Alcohol abuse within 3 month prior IC would interfere trial participation drug abuse . 8 . Participation another trial investigational drug within 2 month prior IC . 9 . Fasting blood glucose &gt; 240 mg/dl ( =13.3 mmol/L ) screening ( Visit 1 ) . 10 . Premenopausal woman ( last menstruation &lt; =1 year prior sign IC ) : nursing pregnant , childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial . Acceptable method birth control include transdermal patch , intra uterine devices/systems ( IUDs/IUSs ) , oral , implantable injectable contraceptive , sexual abstinence vasectomise partner . No exception make . 11 . Treatment systemic steroid change dosage thyroid hormone within six week prior IC 12 . Heart failure New York Heart Asociation ( NYHA ) class IIV , history heart failure . 13 . Diabetic ketoacidosis within 6 month prior IC . 14 . Hemodialyzed patient due limited experience Thiazolidinediones ( TZDs ) 15 . Any clinical condition wich , opinion investigator , would alow safe completion protocol safe administration BI1356 pioglitazone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>